Harvard Bioscience Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2011 Annual Meeting of Stockholders held by Harvard Bioscience, Inc. on May 25, 2011. The filing details the voting results for five specific proposals submitted to shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders voted on the following matters:
- Election of Directors: David Green and John F. Kennedy were elected as Class II Directors for three-year terms.
- Stock Option Plan: The Third Amended and Restated 2000 Stock Option and Incentive Plan was approved.
- Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2011.
- Executive Compensation: Shareholders approved the compensation of named executive officers via a non-binding advisory vote.
- Compensation Vote Frequency: Shareholders recommended an annual (1-year) frequency for future advisory votes on executive compensation.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future operations, or specific risk factors. The document is limited to the reporting of historical voting events.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages.
- Confirm the specific terms of the approved Third Amended and Restated 2000 Stock Option and Incentive Plan.
- Note that 4,398,860 broker non-votes were recorded for the director election and stock plan proposals.
- Confirm the implementation of the annual executive compensation vote frequency as recommended by shareholders.